Latest News for ICCC
PORTLAND, Maine, Feb. 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, expects to report unaudited financial results for the quarter and year ended December 31, 2025 after the market closes on Wednesday, March 4, 2026. The Company is planning to host a…
Shares of ImmuCell Corporation (NASDAQ: ICCC - Get Free Report) passed above its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $6.11 and traded as high as $6.20. ImmuCell shares last traded at $6.02, with a volume of 8,934 shares changing hands. Wall Street
CPIX, NAII and ICCC lean into specialization, compliance and targeted growth to thrive in the niche healthcare markets.
ImmuCell Corporation (ICCC) Q4 2025 Sales/Trading Call Transcript
PORTLAND, Maine, Jan. 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced preliminary, unaudited sales results for the fourth quarter and full year of 2025.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ICCC.
U.S. House Trading
No House trades found for ICCC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.